2. Search Result
Search Result
Results for "

ATP release

" in MedChemExpress (MCE) Product Catalog:

62

Inhibitors & Agonists

2

Screening Libraries

5

Biochemical Assay Reagents

1

Peptides

6

Natural
Products

1

Isotope-Labeled Compounds

1

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B0764
    Bucladesine sodium
    Maximum Cited Publications
    41 Publications Verification

    Dibutyryl cAMP sodium; DBcAMP sodium

    		 PKA Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Bucladesine (Dibutyryl cAMP; DBcAMP) sodium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
    Bucladesine sodium
  • HY-P2764
    Apyrase

    		NTPDase Inflammation/Immunology
    Apyrase is an Nucleoside triphosphate diphosphohydrolase (NTPDase). Apyrase can hydrolyze extracellular adenosine triphosphate (ATP) and adenosine diphosphate (ADP). Apyrase can inhibit Stx2 toxin release of enterohemorrhagic Escherichia coli (EHEC) infection and protect the intestinal barrier function. Apyrase can be used for the research of infection and inflammation, such as hemorrhagic colitis .
    Apyrase
  • HY-14307
    Necrocide 1
    2 Publications Verification

    		 TRP Channel Eukaryotic Initiation Factor (eIF) Reactive Oxygen Species (ROS) Cancer
    Necrocide 1, a necrosis by sodium overload (NECSO) inducer, is a selective transient receptor potential melastatin 4 (TRPM4) agonist with an EC50 of 306.3 nM for human TRPM4. Necrocide 1 triggers TRPM4-dependent necrotic cell death through the induction of sodium influx. Necrocide 1 induces hallmarks of immunogenic cell death incurring calreticulin (CALR) exposure, ATP secretion and high mobility group box 1 (HMGB1) release. Necrocide 1 can be used for the study of breast and prostate cancer .
    Necrocide 1
  • HY-12203
    PFK-158
    10+ Cited Publications

    		 Autophagy Apoptosis Cancer
    PFK-158 is a potent and selective PFKFB3 inhibitor with an IC50 value 137 nM. PFK-158 reduces glucose uptake, ATP production, lactate release, and induces apoptosis and autophagy in cancer cells. PFK-158 has broad anti-tumor activity. PFK-158 can also enhance Colistin's resistance to bacteria .
    PFK-158
  • HY-N2593
    Isorhapontigenin
    4 Publications Verification

    		 Carnitine Palmitoyltransferase (CPT) Reactive Oxygen Species (ROS) Autophagy Apoptosis NF-κB PI3K Akt MMP Keap1-Nrf2 Metabolic Disease Inflammation/Immunology Cancer
    Isorhapontigenin is an orally active dietary polyphenol. Isorhapontigenin acts as a potent antioxidant that reduces the production of reactive oxygen species (ROS). Isorhapontigenin promotes the binding of JUN to the AP-1 site on the SESN2 promoter, induces SESN2 transcription, triggers MAPK8-dependent JUN activation, and upregulates the expression of PPAR-α, PGC-1α and CPT-1A to facilitate fatty acid oxidation. Isorhapontigenin induces autophagy, apoptosis and preadipocyte differentiation; it inhibits tumor growth, cell invasion, NF-κB transcriptional activity, the PI3K/Akt signaling pathway, STAT1 phosphorylation and MMP-2 expression. Isorhapontigenin alleviates oxidative stress, inflammatory cytokine release and triglyceride accumulation; it increases intracellular ATP levels and promotes Nrf2 nuclear translocation. Isorhapontigenin improves insulin sensitivity in adipose tissue and glucose tolerance, and reduces postprandial blood glucose, insulin and free fatty acid levels. Isorhapontigenin is applicable to research on bladder cancer, liver injury, chronic obstructive pulmonary disease, acute lung injury and type 2 diabetes .
    Isorhapontigenin
  • HY-N1502
    Carboxyatractyloside tripotassium
    2 Publications Verification

    Gummiferin tripotassium

    		 Mitochondrial Metabolism Reactive Oxygen Species (ROS) Calcium Channel Neurological Disease
    Carboxyatractyloside tripotassium is a diterpenoid. Carboxyatractyloside tripotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside tripotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside tripotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside tripotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside tripotassium
  • HY-N2522
    Carboxyatractyloside dipotassium
    2 Publications Verification

    Gummiferin dipotassium

    		 Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS) Neurological Disease
    Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside dipotassium
  • HY-116291
    4α-Phorbol 12,13-didecanoate

    4αPDD

    		 TRP Channel CHIKV Infection Inflammation/Immunology
    4α-Phorbol 12,13-didecanoate (4αPDD) is a transient receptor potential vanilloid 4 (TRPV4) agonist. 4α-Phorbol 12,13-didecanoate can promote Ca 2+ influx, induce ATP release and function as an osmoreceptor. 4α-Phorbol 12,13-didecanoate can inhibit water intake and increase maximal micturition pressure in rats. 4α-Phorbol 12,13-didecanoate can be used for the researches of inflammation and infection, such as chikungunya virus (CHIKV) .
    4α-Phorbol 12,13-didecanoate
  • HY-B0764A
    Bucladesine hemicalcium
    Maximum Cited Publications
    41 Publications Verification

    Dibutyryl cAMP hemicalcium; DBcAMP hemicalcium

    		 PKA Apoptosis Reactive Oxygen Species (ROS) Neurological Disease Cancer
    Bucladesine (Dibutyryl cAMP; DBcAMP) hemicalcium is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
    Bucladesine hemicalcium
  • HY-159520
    Ofirnoflastum

    Ofirnoflast; HT-6184

    		 NEKs NOD-like Receptor (NLR) Caspase Apoptosis Pyroptosis NF-κB Cardiovascular Disease Inflammation/Immunology Cancer
    Ofirnoflastum (Ofirnoflast) is an orally active first-in-class allosteric NEK7 inhibitor with an IC50 of 46 nM. Ofirnoflastum binds an allosteric site adjacent to NEK7’s ATP-binding pocket, induces conformational shifts, disrupts NEK7-NLRP3 binding, blocks NLRP3 inflammasome assembly, spares NEK7’s physiological functions, and suppresses caspase-1, caspase-8, NF-κB, and TNF activity. Ofirnoflastum reduces pro-inflammatory cytokine production, suppresses ASC specks, IL-1β release, pyroptotic cell death, and leukemic burden, induces apoptosis and erythroid differentiation, restores hematopoiesis, and improves outcomes in colitis models. Ofirnoflastum can be used for the research of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia .
    Ofirnoflastum
  • HY-119322
    Tifenazoxide

    NN414

    		 Potassium Channel Metabolic Disease
    Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K ATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .
    Tifenazoxide
  • HY-107794
    Clodronate disodium tetrahydrate
    4 Publications Verification

    Disodium clodronate tetrahydrate

    		 Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Clodronate disodium tetrahydrate (Disodium clodronate tetrahydrate) is first-generation bisphosphonate, with anti-osteoporotic, anti-inflammatory and analgesic effects. Clodronate disodium tetrahydrate is a selective, potent, reversible and Cl - competitive vesicular nucleotide transporter (VNUT) inhibitor, with an IC50 of 15.6 nM. Clodronate disodium tetrahydrate inhibits vesicular ATP release from neurons and reduces chronic neuropathic and inflammatory pain .
    Clodronate disodium tetrahydrate
  • HY-B1263
    Chlorobutanol

    		Environmental Pollutants Bacterial Fungal Infection Neurological Disease
    Chlorobutanol is an orally active and potent inhibitor of platelet aggregation and release and a pharmaceutical preservative with antibacterial activity. Chlorobutanol inhibits thromboxane B2 formation, ATP release, and elevation of cytosolic free calcium caused by collagen, ADP, epinephrine, arachidonic acid and thrombin. Chlorobutanol is active against a wide variety of Gram-positive and Gram-negative bacteria, and several mold spores and fungi. Chlorobutanol is widely used in food and cosmetic industry .
    Chlorobutanol
  • HY-W039315
    2,5-Anhydro-D-mannitol, 97%

    		Biochemical Assay Reagents Metabolic Disease
    2,5-Anhydro-D-mannitol, 97% is an antimetabolic fructose analogue. 2,5-Anhydro-D-mannitol, 97% depletes intracellular ATP, reduces oxygen consumption, regulates substrate oxidation, increases phosphomonoester levels, decreases inorganic phosphate levels, and promotes the release of intracellular calcium from intracellular calcium stores via phospholipase C-dependent activity in hepatocytes .
    2,5-Anhydro-D-mannitol, 97%
  • HY-P1137
    10Panx
    1 Publications Verification

    		 Gap Junction Protein Others
    10Panx is a competitive inhibitor of selective Pannexin 1 (PANX1) channels. 10Panx blocks the opening of PANX1 channels, inhibits ATP release and downstream P2X7 receptor-mediated signaling pathways, thereby reducing cell death and inflammatory responses. 10Panx can be used in the study of diseases such as neuropathic pain, inflammatory bowel disease, and Clostridioides difficile infection. 10Panx can effectively reduce mechanical hyperalgesia and enhanced C-reflexes, and inhibit the expression of pro-inflammatory factors such as IL-6[1][2][3].
    10Panx
  • HY-139109
    IR-783
    2 Publications Verification

    ADS 780WS

    		 Fluorescent Dye Apoptosis Mitochondrial Metabolism ATP Synthase Cytochrome P450 Dynamin Cancer
    IR-783 (ADS 780WS) is a heptamethine cyanine dye. IR-783 induces Mitochondrial membrane potential loss, ATP depletion, mitochondrial permeability transition pore opening, Cytochrome c release and Apoptosis in breast cancer cells. IR-783 promotes the translocation of Drp1 from the cytosol to mitochondria. IR-783 increases the expression of mitochondrial fission proteins such as MFF and Fission-1. IR-783 possesses imaging, cancer-targeting and anticancer properties. IR-783 exerts anticancer effects against breast cancer. IR-783 can be used in breast cancer-related research .
    IR-783
  • HY-108667
    TNP-ATP triethylammonium

    		P2X Receptor Interleukin Related Fluorescent Dye Neurological Disease
    TNP-ATP triethylammonium is a P2X receptor antagonist with an IC50 of 0.010 μM for P2X3 and an IC50 of 0.062 μM for P2X2/3. TNP-ATP triethylammonium acts as an inhibitor of CheA autophosphorylation, with a Ki of 0.7 µM. TNP-ATP triethylammonium blocks the functional activation of P2X1-7 receptors. TNP-ATP triethylammonium attenuates hypoxia-induced IL-1β expression and release. TNP-ATP triethylammonium alleviates visceral pain, and improves hypoxia-induced cognitive impairment, insufficient myelination and neuroinflammation. Binding of TNP-ATP triethylammonium to CheA enhances the fluorescence of the TNP group. TNP-ATP triethylammonium can be used in studies related to visceral pain. NP-ATP triethylammonium can be used in studies related to hypoxia-induced insufficient myelination and cognitive decline .
    TNP-ATP triethylammonium
  • HY-126328
    PKC-theta inhibitor 1

    		PKC Interleukin Related Inflammation/Immunology
    PKC-theta inhibitor 1 is an orally active and selective ATP-competitive inhibitor of Protein Kinase Cθ (PKCθ), with a Ki value of 6 nM. PKC-theta inhibitor 1 inhibits T-cell-mediated inflammatory responses by suppressing the release of proinflammatory cytokines (IL-2 IC50 = 0.21 μM in anti-CD3/CD28-stimulated PBMCs; IL-17 IC50 = 1 μM in CD3/CD28-stimulated Th17 cells) PKC-theta inhibitor 1 significantly reduces symptoms in mice with ongoing experimental autoimmune encephalomyelitis (EAE). PKC-theta inhibitor 1 can be used for the study of T-cell-mediated inflammatory diseases such as multiple sclerosis .
    PKC-theta inhibitor 1
  • HY-112390A
    Syk Inhibitor II
    2 Publications Verification

    		 Syk 5-HT Receptor Inflammation/Immunology
    Syk Inhibitor II is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II shows less potent against other kinases and has anti-allergic effect .
    Syk Inhibitor II
  • HY-W012985
    Methyl pyruvate

    		ATP Synthase Apoptosis Metabolic Disease Cancer
    Methyl pyruvate is a methyl ester derivative of pyruvic acid. Methyl pyruvate induces insulin release and membrane depolarization. Methyl pyruvate rescues proteasome damage and nuclear localization of TdP-43 caused by overexpression of σ1RE102Q by enhancing ATP synthesis. Methyl pyruvate selectively protects normal lung fibroblasts from cell death induced by Irinotecan (HY-16562). Methyl pyruvate promotes apoptosis and necrosis in cancer cells and downregulates angiogenesis and cell cycle pathways. Methyl pyruvate is an effective substrate for dihydrodihydrogen dehydrogenase.
    Methyl pyruvate
  • HY-B0764B
    Bucladesine

    Dibutyryl cAMP; DBcAMP

    		 PKA Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
    Bucladesine
  • HY-158664
    2-Amino-ATP sodium solution (100 mM)

    		Biochemical Assay Reagents DNA/RNA Synthesis Others
    2-Amino-ATP sodium solution (100 mM) is a labeled modified deoxyoligonucleotide (dNTP) that can release pyrophosphate to produce fluorescence and has special applications in gene synthesis and sequencing .
    2-Amino-ATP sodium solution (100 mM)
  • HY-117432
    JC-171

    		NOD-like Receptor (NLR) Inflammation/Immunology
    JC-171 is a selective NLRP3 inflammasome inhibitor, with an IC50 of 8.45 μM for inhibiting LPS/ATP-induced interleukin-1β (IL-1β) release from J774A.1 macrophages .
    JC-171
  • HY-130354
    Dibutyryl-cGMP sodium
    2 Publications Verification

    Bt2cGMP sodium

    		 Potassium Channel Cardiovascular Disease
    Dibutyryl-cGMP sodium (Bt2cGMP sodium) is a cell-permeable cGMP analogue. Dibutyryl-cGMP sodium preferentially activates cGMP-dependent protein kinase (PKG). Dibutyryl-cGMP sodium inhibits the release of [ 3H]-arachidonic acid from γ thrombin-stimulated human platelets. Dibutyryl-cGMP sodium induces peripheral antinociception via activation of ATP-sensitive K + channels .
    Dibutyryl-cGMP sodium
  • HY-161671
    GAT2711

    		nAChR Neurological Disease Inflammation/Immunology
    GAT2711 is a full agonist of α9 nAChR with an EC50 of 230 nM. GAT2711 shows 340-fold selective for α9 over α7 nAChRs. GAT2711 inhibits ATP-induced IL-1β release in THP-1 cells. GAT2711 retains full analgesic activity in α7 nAChR knockout mice .
    GAT2711
  • HY-B0764G
    Bucladesine sodium

    Dibutyryl cAMP sodium; DBcAMP sodium

    		 PKA Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (GMP) is a Bucladesine sodium (HY-B0764) produced by using GMP guidelines. Bucladesine (Dibutyryl cAMP; DBcAMP) is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
    Bucladesine sodium
  • HY-120048
    NBC19

    		NOD-like Receptor (NLR) Inflammation/Immunology
    NBC19 is an NLRP3 inflammasome inhibitor with an IC50 of 60 nM in differentiated THP1 cells. NBC19 inhibits nigericin- and ATP-induced IL-1β release with IC50s of 80 nM and 850 nM, respectively .
    NBC19
  • HY-19888
    GSK-1482160

    		P2X Receptor Interleukin Related Neurological Disease Inflammation/Immunology
    GSK-1482160 is an orally active and blood-brain barrier penetrant P2X7 receptor (P2X7R) negative allosteric modulator with pIC50s of 8.5 (human) and 6.5 (rat). GSK-1482160 reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity, thereby inhibiting the release of IL-1β. GSK-1482160 is an effective radioligand and can be labeled with radioactive isotopes like 11C or 18F to image P2X7R. GSK-1482160 can be used for the studies of chronic joint pain and chronic constriction injury (CCI) .
    GSK-1482160
  • HY-B0764R
    Bucladesine sodium (Standard)

    Dibutyryl cAMP sodium (Standard); DBcAMP sodium (Standard)

    		 Reference Standards PKA Reactive Oxygen Species (ROS) Apoptosis Neurological Disease Inflammation/Immunology Cancer
    Bucladesine (Dibutyryl cAMP; DBcAMP) sodium (Standard) is the analytical standard of Bucladesine sodiumn (HY-B0764). This product is intended for research and analytical applications. Bucladesine is a membrane-permeable 3′, 5′-cyclic adenosine monophosphate (cAMP) analog. Bucladesine selectively activates cAMP dependent protein kinase (PKA) by increasing the intracellular level of cAMP. Bucladesine significantly attenuates MDMA-induced increases in hippocampal mitochondrial ROS formation, mitochondrial outer membrane damage, cytochrome c release, and hippocampal ADP/ATP ratio, thereby improving spatial learning and memory impairments. Bucladesine exhibit anti-nociceptive and anti-inflammation effect. Bucladesine can inhibit cancer cells proliferation, induce apoptosis. Bucladesine can be used for the researches of neurological disease, cancer, inflammation .
    Bucladesine sodium (Standard)
  • HY-108670
    AZ 11645373

    		P2X Receptor Inflammation/Immunology
    AZ11645373 is a highly selective and potent antagonist at human but not rat P2X7 receptors，AZ11645373 inhibits ATP-evoked IL-1β release from lipopolysaccharide-activated THP-1 cells , with an IC50 value of 90 nM .
    AZ 11645373
  • HY-175645
    NLRP3/URAT1-IN-1

    		NOD-like Receptor (NLR) URAT1 Interleukin Related OAT GLUT Metabolic Disease Inflammation/Immunology
    NLRP3/URAT1-IN-1 is an orally active double inhibitor of NLRP3 and URAT1 (IC50 = 3.81 μM). NLRP3/URAT1-IN-1 inhibits IL-1β release in LPS (HY-D1056) and ATP-stimulated mouse bone marrow-derived macrophages (BMDMs), with an IC50 of 2.61 μM. NLRP3/URAT1-IN-1 reduces serum uric acid (SUA) and alleviates liver/kidney damage in mice with acute hyperuricemia (HUA). NLRP3/URAT1-IN-1can be used for the study of gout and hyperuricemia .
    NLRP3/URAT1-IN-1
  • HY-137418
    2-MeS-ATP

    2-Methylthio-ATP

    		 P2Y Receptor Others Inflammation/Immunology
    2-MeS-ATP (2-Methylthio-ATP) is an analog of adenosine nucleotides and acts as a P2Y purinergic receptor agonist specific for adenosine nucleotide activation. 2-MeS-ATP is also able to inhibit the release of toxic mediators from macrophages stimulated by endotoxin (LPS). 2-MeS-ATP can be used in the study of endotoxin shock and inflammatory diseases .
    2-MeS-ATP
  • HY-112390
    Syk Inhibitor II dihydrochloride

    		5-HT Receptor Syk Inflammation/Immunology
    Syk Inhibitor II dihydrochloride is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II dihydrochloride inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II dihydrochloride shows less potent against other kinases and has anti-allergic effect .
    Syk Inhibitor II dihydrochloride
  • HY-123659
    KR-33028

    		Na+/H+ Exchanger (NHE) Apoptosis Cardiovascular Disease Cancer
    KR-33028 is a selective NHE1 inhibitor. KR-33028 reduces hypoxia-induced necrosis and apoptosis in H9c2 cells. KR-33028 inhibits hypoxia-induced increases in cytoplasmic and mitochondrial Ca 2+ levels and cytochrome c release. KR-33028 improves cardiac contractility, reduces lactate dehydrogenase release, and increases tissue ATP, creatine phosphate, and glycogen levels. KR-33028 can be used in research on cancers such as cardioblastoma and cardiovascular diseases such as ischemic stroke .
    KR-33028
  • HY-B1588S
    Carbenoxolone-d4

    		Amyloid-β HIV 11β-HSD Infection Neurological Disease Inflammation/Immunology
    Carbenoxolone-d4 is deuterium labeled Carbenoxolone. Carbenoxolone, a semi-synthetic derivative of glycyrrhetinic acid, has previously been used for the management of dyspepsia and peptic ulcer because of its anti-inflammatory properties . Carbenoxolone, a general hemichannel and gap junction inhibitor, has the therapeutic potential of carbenoxolone in the research of chronic liver disease . Carbenoxolone is a suitable candidate for the inhibition of Aβ42 aggregation and the therapeutic potential of Cbx against AD . Carbenoxolone is small molecule Pannexin1 (Panx1,is an ATP release channel) inhibitor, attenuate Panx1 channel activity through modulation of the first extracellular loop .Carbenoxolone is an 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor that converts inactive glucocorticoid into an active form. Carbenoxolone has antiviral activity against DENV infection targeting the virus itself .
    Carbenoxolone-d4
  • HY-105120A
    Vapiprost hydrochloride

    GR 32191 hydrochloride

    		 Prostaglandin Receptor Others
    Vapiprost hydrochloride (GR 32191 hydrochloride) is a thromboxane A2 receptor antagonist. Vapiprost hydrochloride (GR 32191 hydrochloride) inhibits the aggregation and ATP release stimulated with U-46619, collagen or arachidonic acid (AA) at an IC50 of less than 2.1×10 -8 M .
    Vapiprost hydrochloride
  • HY-158663
    N,N-Dimethyl-ATP sodium

    		Biochemical Assay Reagents DNA/RNA Synthesis Others
    N,N-Dimethyl-ATP sodium is a labeled modified deoxyoligonucleotide (dNTP) that can release pyrophosphate to produce fluorescence and has special applications in gene synthesis and sequencing .
    N,N-Dimethyl-ATP sodium
  • HY-158665
    3'-Deoxy-3'-amino-ATP sodium

    		Biochemical Assay Reagents DNA/RNA Synthesis Others
    3'-Deoxy-3'-amino-ATP sodium is a labeled modified deoxyoligonucleotide (dNTP) that can release pyrophosphate to produce fluorescence and has special applications in gene synthesis and sequencing .
    3'-Deoxy-3'-amino-ATP sodium
  • HY-105120
    Vapiprost

    GR 32191

    		 Prostaglandin Receptor Others
    Vapiprost (GR 32191) is a thromboxane A2 receptor (TXA2 Receptor) antagonist. Vapiprost hydrochloride (GR 32191 hydrochloride) inhibits the aggregation and ATP release stimulated with U-46619, collagen or arachidonic acid (AA) at an IC50 of less than 2.1×10 -8 M .
    Vapiprost
  • HY-165363
    AK-135 hydrochloride

    		Drug Derivative Lactate Dehydrogenase ATP Synthase Cardiovascular Disease
    AK-135 hydrochloride is a Menadione (HY-B0332) derivative. AK-135 hydrochloride restores the electron flow in defective respiratory chain systems. AK-135 hydrochloride decreases LDH release, increases the amount of ATP. AK-135 hydrochloride has a protective effect against myocardial injury .
    AK-135 hydrochloride
  • HY-112390C
    Syk Inhibitor II hydrochloride

    		5-HT Receptor Syk Inflammation/Immunology
    Syk Inhibitor II hydrochloride is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II hydrochloride inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II hydrochloride shows less potent against other kinases and has anti-allergic effect .
    Syk Inhibitor II hydrochloride
  • HY-168474
    P2X4 antagonist-4

    		P2X Receptor Inflammation/Immunology
    P2X4 antagonist-4 (compound 64) is a potent P2X4R antagonist with an IC50 value of 8 µM. P2X4 antagonist-4 blocks the ATP-induced NLRP3 inflammasome activation and release of IL-1β .
    P2X4 antagonist-4
  • HY-N2522R
    Carboxyatractyloside dipotassium (Standard)

    Gummiferin dipotassium (Standard)

    		 Reference Standards Mitochondrial Metabolism Calcium Channel Reactive Oxygen Species (ROS) Neurological Disease
    Carboxyatractyloside (dipotassium) (Standard) is the analytical standard of Carboxyatractyloside dipotassium (HY-N2522). This product is intended for research and analytical applications. Carboxyatractyloside dipotassium is a diterpenoid. Carboxyatractyloside dipotassium can be isolated from plants of the genus Xanthium. Carboxyatractyloside dipotassium is an ADP/ATP carrier inhibitor, inhibiting mitochondrial ADP/ATP transport. Carboxyatractyloside dipotassium promotes ROS production, induces Ca 2+ release, and leads to mitochondrial dysfunction. Carboxyatractyloside dipotassium induces lethargy, weakness, and epileptic seizures in rats .
    Carboxyatractyloside dipotassium (Standard)
  • HY-112390B
    Syk Inhibitor II dihydrochloride dihydrate

    		Syk 5-HT Receptor Inflammation/Immunology
    Syk Inhibitor II dihydrochloride dihydrate is a potent, high selective and ATP-competitive Syk inhibitor with an IC50 of 41 nM. Syk Inhibitor II dihydrochloride dihydrate inhibits 5-HT release from RBL-cells with an IC50 of 460 nM. Syk Inhibitor II dihydrochloride dihydrate shows less potent against other kinases and has anti-allergic effect .
    Syk Inhibitor II dihydrochloride dihydrate
  • HY-19216
    KR-30450

    SKP 450

    		 Potassium Channel Cardiovascular Disease
    KR-30450 (SKP 450) is a potent K +ATP opener, and a potassium channel activator. KR-30450 exerts more potent cardioprotective effects than Lemakalim (HY-14255). KR-30450 significantly improves reperfusion cardiac function. KR-30450 significantly attenuates reperfusion contracture and lactate dehydrogenase release .
    KR-30450
  • HY-N12235
    Sarglaroids F

    		Caspase Inflammation/Immunology
    Sarglaroids F (compound 6) is an anti-inflammatory agent isolated from the roots of Grass Coral. Sarglaroids F inhibits LPS/ATP-induced IL-1β release by affecting K+ efflux and reducing Caspase-1(P20) levels. Sarglaroids F is not cytotoxic to RAW264.7 cells .
    Sarglaroids F
  • HY-159560
    PBA-AMF

    		Apoptosis DNA/RNA Synthesis Cancer
    PBA-AMF can be activated by H2O2 to release Amonafide (AMF) (HY-10982). PBA-AMF selectively inhibited the proliferation of breast cancer cells, while sparing non-cancerous cells. PBA-AMF inhibits tumor proliferation by inhibiting DNA synthesis, reducing ATP levels, inducing apoptosis, and arresting the cell cycle. PBA-AMF can be used for research of tumors and other diseases associated with increased H2O2 levels .
    PBA-AMF
  • HY-107794R
    Clodronate disodium tetrahydrate (Standard)

    Disodium clodronate tetrahydrate (Standard)

    		 Others Reference Standards Neurological Disease Inflammation/Immunology Cancer
    Clodronate (disodium tetrahydrate) (Standard) is the analytical standard of Clodronate (disodium tetrahydrate). This product is intended for research and analytical applications. Clodronate disodium tetrahydrate (Disodium clodronate tetrahydrate) is first-generation bisphosphonate, with anti-osteoporotic, anti-inflammatory and analgesic effects. Clodronate disodium tetrahydrate is a selective, potent, reversible and Cl-competitive vesicular nucleotide transporter (VNUT) inhibitor, with an IC50 of 15.6 nM. Clodronate disodium tetrahydrate inhibits vesicular ATP release from neurons and reduces chronic neuropathic and inflammatory pain .
    Clodronate disodium tetrahydrate (Standard)
  • HY-15026
    ATB 429

    		Endogenous Metabolite Inflammation/Immunology
    ATB-429, a novel H2S-releasing derivative of mesalamine, demonstrates significant anti-nociceptive and anti-inflammatory effects in models of irritable bowel syndrome (IBS). By releasing hydrogen sulfide (H2S), ATB-429 modulates colorectal distension-induced hypersensitivity in both healthy and postcolitic rats. It attenuates abdominal withdrawal responses and suppresses spinal c-Fos mRNA expression, indicating its potential to alleviate pain associated with gastrointestinal inflammation. Moreover, ATB-429 down-regulates colonic cyclooxygenase-2 and interleukin-1β mRNA expression, effects not observed with mesalamine alone. The mechanism involves ATP-sensitive K+ (KATP) channels, as evidenced by reversal of ATB-429's effects with glibenclamide. These findings suggest ATB-429 could offer therapeutic benefits for managing painful intestinal disorders linked to inflammation .
    ATB 429
  • HY-123382
    GSK-1482160 (isomer)

    		Drug Isomer Neurological Disease Inflammation/Immunology
    GSK-1482160 isomer is the isomer of GSK-1482160 (HY-19888). GSK-1482160 is an orally active and blood-brain barrier penetrant P2X7 receptor (P2X7R) negative allosteric modulator with pIC50s of 8.5 (human) and 6.5 (rat). GSK-1482160 reduces the efficacy of ATP at the P2X7 receptor without affecting its affinity, thereby inhibiting the release of IL-1β. GSK-1482160 is an effective radioligand and can be labeled with radioactive isotopes like 11C or 18F to image P2X7R. GSK-1482160 can be used for the studies of chronic joint pain and chronic constriction injury (CCI).
    GSK-1482160 (isomer)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: